Profiles of gut microbiota associated with clinical outcomes in patients with different stages of SARS-CoV-2 infection

• Published in: Life sciences (1973) Vol. 332; p. 122136
• Main Authors: Krasaewes, Kawisara, Chaiwarith, Romanee, Chattipakorn, Nipon, Chattipakorn, Siriporn C.
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 01.11.2023
• Subjects: Acute; antimicrobial peptides; biomarkers; COVID-19; COVID-19 infection; digestive tract; disease severity; dysbiosis; Gut dysbiosis; Gut microbiota; intestinal microorganisms; Post; prediction; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; species; species diversity; therapeutics; PICO; Gut microbiota; CXCL; M-CSF; PACS; PT; 3-IPA; ALT; DM; AUC; COVID-19; HDL-C; IFN-α; QA; ↑; RBC; SARS-CoV-2; ↓; ↔; Pecam1; mTOR; BSI; LBP; ∝; ARDS; PFT; WHO; AA; IL; MDRB; ROC; 3-HAA; G-CSF; ACE2; LOS; NEUT; CAP; IMV; Dpi; Met; Camp; DBIL; BA; CRP; PCT; NS; VTE; TMPRSS2; F/U; ABO; LPS; LDH; Ocln; S; DLCO; KA; PLT; WBC; AKI; Dys; AST; GI; Tie1; Acute; Post; CK; EOS; γ-GT; NASH; CCL; Vegfr1; TC; PMN; APTT; MIS-C; TG; TNF-α; PE; NK cell; SCFAs; Apj; ICU; Gut dysbiosis; HC; HD; Zo1; ILA
• ISSN: 0024-3205; 1879-0631; 1879-0631
• DOI: 10.1016/j.lfs.2023.122136

The correlation between SARS-CoV-2 infection and gut microbiota has been a subject of growing interest in recent research endeavors. It is postulated that SARS-CoV-2 might lead to gut dysbiosis by affecting the gut-lung axis and reducing the production of antimicrobial peptides in the gastrointestinal tract. Our comprehensive review of both in vivo and clinical studies has revealed a consistent decline in alpha diversity and increased dissimilarity in beta diversity of gut microbiota in comparison to healthy populations, observed during both the acute and post-infection phases of COVID-19. Furthermore, there is a notable reduction in the number of beneficial butyrate-producing bacteria, alongside an upsurge in opportunistic bacteria. Concomitantly, the functional and metabolic characteristics of gut microbiota are significantly altered. Consequently, COVID-19 patients exhibit a heightened inflammatory state, which has been linked to the severity of the disease in the acute phase and the occurrence of post-acute COVID-19 syndrome (PACS) in the post-infection phase. Notably, certain specific gut microbiota species have emerged as potential candidates for aiding in the diagnosis, prediction of disease severity, or treatment of severe cases of COVID-19. This review also underscores the significance of gut microbiota in the context of post-acute COVID-19 syndrome (PACS) and offers valuable insights into possible biomarkers for diagnosis and therapeutic targets for PACS in the future. [Display omitted] •Gut dysbiosis has been observed in both acute and post-SARS-CoV2 infections for up to 1 year.•In acute COVID-19, some species of gut microbiota were correlated with disease severity.•In post COVID-19, some species of gut microbiota were associated with post-acute COVID-19 syndrome (PACS).•Modulating gut microbiota may be a therapeutic approach for severe COVID-19 and PACS.•Some specific species of gut microbiota may be used as a biomarker for predicting PACS.